Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

Parties have already agreed to sell more than 50 products so far, but are still extending outside date for closing of Teva's acquisition of Allergan's generic business until October.

Analysts had been expecting Teva's acquisition of Allergan's generics business to close at the end of June; Teva insists the acquisition is still going to plan.